Enzymatica announces new dates for its financial information
March 15 2016 - 9:42AM
Due to the decision of new rights
issue of SEK 60 M after the acquisition of the Icelandic company
Zymetech, and the Extraordinary General Meeting to be held on April
14 for approval of the rights issue Enzymatica has changed dates
for the announcement of its financial information.
New dates:
Q1 Interim report: 18 April
Issue of the annual report 2015: at the latest 27 April
Annual General Meeting: 25 May
For
more information, please contact:
Fredrik Lindberg, CEO Enzymatica AB
Tel: +46 708-86 53 70 | E-post: fredrik.lindberg@enzymatica.com
About Enzymatica AB
Enzymatica is a life science company who develops and sells medical
device products against infectious-related diseases. Over a short
period the company has developed a unique oral spray for colds,
ColdZyme®, and launched it on six markets. The product has become
one of the leading articles for colds in Swedish pharmacies.
Enzymatica's strategy is to continue growing by strengthening its
position in existing markets and to expand to more geographical
markets through well-established partners. The company is
headquartered in Lund, Sweden and is listed on Nasdaq First North.
For more information, please visit www.enzymatica.com.
Enzymatica's certified adviser is Erik Penser
Bankaktiebolag.
Press Release (PDF)
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Enzymatica AB via Globenewswire
HUG#1994499
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024